eli lilly retatrutide trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide, Eli Lilly's next obesity

The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD)

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

doi: 10.12688/f1000research.125549.3 8 HaileTGMariyeTTadesseDBGebremeskelGGAsefaGGGetachewT

S.NielsenO

In 2026, none of the Bridge drugs are subject to an MFP

(This study needs some review and scrutiny, but that is for another post)